You are not currently logged in.
Access JSTOR through your library or other institution:
In vitro Activity of Doripenem
Clinical Infectious Diseases
Vol. 49, Supplement 1. Doripenem: A New Carpabenem in the Treatment of Nosocomial Infection (Aug. 15, 2009), pp. S11-S16
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/40308094
Page Count: 6
You can always find the topics here!Topics: Carbapenems, Pathogens, Antimicrobials, Microbial sensitivity tests, Pseudomonas aeruginosa, Enterobacteriaceae, Antibiotics, Phenotypes, Infections, Surveillance
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Doripenem is a carbapenem antibiotic that covers a wide range of gram-positive and gram-negative pathogens. In vitro studies have provided insight into certain features of doripenem's activity profile that may have particular relevance in the clinical setting. For instance, in vitro data indicate that doripenem combines the intrinsic activity of meropenem against gram-negative pathogens with the intrinsic activity of imipenem against gram-positive pathogens. Also notable is the fact that the in vitro activity of doripenem against problematic gram-negative pathogens, in particular Pseudomonas aeruginosa, is potent—recent data show that the minimum concentration necessary for inhibition of 90% of all isolates (MIC₉₀) of doripenem with respect to P. aeruginosa (4µg/mL) is 2-4 times lower than the corresponding MIC₉₀, values of meropenem and imipenem. Furthermore, doripenem shows a limited ability to select for carbapenem-resistant mutants in vitro. Such experimental findings suggest that doripenem may represent a valuable option when carbapenem therapy is warranted for the treatment of serious infection.
Clinical Infectious Diseases © 2009 Oxford University Press